// App-Quantinova.ai

POS1037 (2022) : EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS

Researchers

Presenter

  • P. J. Mease

Principal Investigators

  • P. Helliwell

  • D. D. Gladman

  • D. Poddubnyy

  • X. Baraliakos

  • S. D. Chakravarty

  • A. Kollmeier

  • X. L. Xu

  • S. Sheng

  • S. Xu

  • M. Shawi

  • D. Van der Heijde

  • A. Deodhar

Medical Centers

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Toronto Western Hospital and University of Toronto, Department of Medicine, Ontario, Canada

  • Charite Universitatsmedizin Berlin Campus Benjamin Franklin, Infectious Diseases and Rheumatology, Berlin, Germany

  • German Rheumatism Research Centre, Department of Rheumatology, Berlin, Germany

  • Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

  • Janssen Scientific Affairs, LLC, Department of Dermatology, Horsham, PA, United States of America

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

  • Janssen Global Services, LLC, Global Medical Affairs, Horsham, PA, United States of America

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

Locations

  • United States

  • United Kingdom

  • Canada

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Sacroiliitis

Biomarkers

  • C reactive protein

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved